What is the Optimal Treatment Strategy for T1 Bladder Tumors?

European Urology

Volumn 57, Issue 1, 2010, Pages 32-34

  Babjuk, Marko ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; EPIRUBICIN; MITOMYCIN C;

BLADDER CANCER; CANCER IMMUNOTHERAPY; CARCINOMA IN SITU; EDITORIAL; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; TRANSURETHRAL RESECTION; TREATMENT PLANNING;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCG VACCINE; CARCINOMA; CYSTECTOMY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; EPIRUBICIN; HUMANS; INTERFERON ALFA-2B; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; REOPERATION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; URINARY BLADDER NEOPLASMS;

EID: 70449529323     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.10.015     Document Type: Editorial

References (12)

1. Fernandez-Gomez J., Solsona E., Unda M., et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 53 (2008) 992-1002
2. Duchek M., Johansson R., Jahnson S., et al. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-α2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective randomized Nordic study. Eur Urol 57 (2010) 25-31
3. Brausi M.A., Gavioli M., Peracchia G., et al. Dedicated teaching programs can improve the quality of TUR of non-muscle-invasive bladder tumors (NMIBT): experience of a single institution. Eur Urol Suppl 7 (2008) 180
4. Grossman H.B., Gomella L., Fradet Y., et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178 (2007) 62-67
5. Denzinger S., Wieland W.F., Otto W., Filbeck T., Knuechel R., and Burger M. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 101 (2008) 566-569
6. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
7. Divrik R.T., Yildrim U., Zorlu F., et al. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial. J Urol 175 (2006) 1641-1644
8. Sylvester R., Oosterlinck W., and van der Meijden A. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
9. Malmström P.-U., Sylvester R.J., Crawford D.E., et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 56 (2009) 247-256
10. Sylvester R.J., van der Meijden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
11. Schrier B.P., Hollander M.P., van Rhijn B.W.G., Kiemeney L.A.L.M., and Witjes J.A. Prognosis of muscle invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45 (2004) 292-296
12. Lambert E.H., Pierorazio P.M., Olsson C.A., Benson M.C., McKiernan J.M., and Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 100 (2007) 33-36